Biotech Startups

VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.

6 investors

Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.

6 investors

Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.

6 investors

Transforming the lives of patients through a functional cure for Type 1 Diabetes

6 investors

Violet is a therapeutics company developing small molecule treatments for central nervous system diseases, using its proprietary C-to-C Engine platform to identify disease-relevant cell-to-cell interactions. Its lead program is a small molecule inhibitor of EphB3, a receptor tyrosine kinase involved in microglia-astrocyte interactions linked to glial dysfunction in neurodegenerative disease.

6 investors

Virtual Incision develops a miniaturized robotic-assisted surgery (miniRAS) system called MIRA, designed to fit within hospitals' existing infrastructure. The company targets patients, surgeons, and healthcare facilities in the surgical robotics and medical device market.

6 investors

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis. Its pipeline is built on technologies licensed from FIMA at the University of Navarra in Spain.

6 investors

Volta develops a hardware and software platform for genomics sample preparation that automates the extraction of biological information. The company serves researchers, laboratories, and healthcare organizations working in genomics, disease control, forensic science, and medicine.

6 investors

Weave Bio builds AI-assisted software for regulatory teams in drug development to author, organize, and manage eCTD submission content across the regulatory lifecycle, covering documents from investigator's brochures and clinical study reports through IND, NDA, and BLA development. The platform supports content drafting, source traceability, collaborative review, and secure export into systems such as Veeva.

6 investors

Y-Biologics (와이바이오로직스) develops antibody-based drugs using its antibody discovery, fully human antibody library, and antibody engineering technologies, working through its own pipeline and partner collaborations. Its programs include next-generation immuno-oncology therapies such as Multi-AbKine, a multi antibody-cytokine fusion aimed at cancers resistant to existing immunotherapies, along with bispecific antibodies, VHH nanobodies, pH-sensitive antibodies, and ADC antibodies.

6 investors

Yemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.

6 investors

YourChoice Therapeutics is developing YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials. The company targets male contraceptive users seeking alternatives to condoms or vasectomy.

6 investors

Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D. It operates as a royalty-driven organization that builds and manages a portfolio of healthcare assets through partnerships and collaborations across multiple therapeutic areas.

6 investors

Zymvol develops custom-made enzymes using computational methods for industrial applications across various sectors. The company enables manufacturers to adopt biocatalytic solutions as a sustainable alternative to traditional chemical processes.

6 investors

Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.

6 investors

Dioseve develops reproductive cell technology that uses a proprietary differentiation-induction method to generate oocytes and ovarian somatic cells from iPS cells. The company targets fertility and infertility challenges, aiming to help people who want to have children, particularly around age-related declines in egg and sperm function.

6 investors

Oxford Cancer Analytics develops a diagnostics platform that combines reproducible proteomic measurement with AI to produce evidence-based insights supporting clinical decision-making. Its focus is on lung disease, beginning with Chronic Obstructive Pulmonary Disease (COPD) and extending to conditions such as lung cancer.

5 investors

52North Health develops NeutroCheck, a diagnostic tool that identifies neutropenia in chemotherapy patients presenting with fever, enabling risk stratification and reducing unnecessary emergency department visits.

5 investors

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.

5 investors

AbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.

5 investors

Abion is a biotech company focused on precision oncology, researching and developing novel anticancer drugs. It works to identify and commercialize new drug candidates and conduct global clinical trials for rare and hard-to-treat diseases, partnering with domestic and international biopharma companies.

5 investors

Abogen is a biotechnology company developing mRNA-based therapeutics and vaccines, including an mRNA shingles vaccine and mRNA-encoded T-cell engagers for cancer such as B-cell non-Hodgkin lymphoma. Its work spans preclinical research and clinical-stage programs in RNA technology and lipid nanoparticle formulation.

5 investors

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients. It operates in oncology-focused drug discovery and development.

5 investors

Acesion Pharma is a biotech company developing pharmaceutical treatments. This page presents its leadership team and board of directors.

5 investors